



**Health, Seniors and Long-Term Care
Public Health**

300 Carlton Street
Winnipeg, Manitoba Canada R3B 3M9

September 16, 2025

RE: Expanded Paediatric RSV Immunoprophylaxis Program

Beginning October 1, 2025, all infants born October 1, 2025 to March 31, 2026 will be eligible for one dose of nirsevimab.

This is in addition to the existing eligibility criteria where infants and children with the following high-risk conditions may be eligible in consultation with the Manitoba High-Risk RSV Immunoprophylaxis Program:

- Preterm infants born before 33 weeks gestational age between April 1 and September 30, 2025;
- Children with cardiac conditions < 2 years of age on October 1, 2025 (in consultation with pediatric cardiology)*;
- Children with chronic lung conditions, typically requiring supplemental oxygen treatment, < 2 years of age on October 1, 2025*;
- Other patients in consultation with the Manitoba High-Risk RSV Immunoprophylaxis Program*.

*Eligibility for these infants will be determined on a case-by-case basis by the Manitoba High-Risk RSV Immunoprophylaxis Program with specialist consultation as needed.

Manitoba Health Seniors and Long-Term Care (MHS LTC) is asking health care providers to share information about the RSV Immunoprophylaxis Program's expanded eligibility criteria to expecting parents in advance of the RSV season to promote uptake and potentially reduce hospitalizations related to RSV.

- Nirsevimab (RSV Monoclonal Antibody) Fact Sheet:
<https://www.gov.mb.ca/health/publichealth/factsheets/nirsevimab-rsv-monoclonal-antibody.pdf>

Nirsevimab will be offered to all infants born October 1, 2025 to March 31, 2026 at various sites throughout the province. Infants born in birthing hospitals can receive nirsevimab prior to discharge. If an infant does not receive a dose prior to discharge, parents can be directed to the following locations where providers can administer a dose:

- Local public health office or post-partum home visit by the public health nurse;
- A nursing station or health centre;

- Designated Walk-In Connected Care Clinics at Access Centres in Winnipeg. Call the clinic first to confirm availability: wrha.mb.ca/locations-services/walk-in-connected-care/.

Health care providers should document administration of nirsevimab using the RSV Monoclonal Antibody Administration Reporting Form for Health Care Providers (<https://www.gov.mb.ca/health/publichealth/cdc/div/manual/docs/rsv-monoclonal-ab-administration-form.pdf>) and fax it to 204-945-6482.

More information about the program can be found at: <https://www.gov.mb.ca/health/publichealth/diseases/rsv.html>

Please share this information with all colleagues at your facility/clinic.

Sincerely,

“Original Signed by”

Richard Baydack, PhD
Executive Director
Communicable Disease Prevention and Control

“Original Signed by”

Natalie Casalang, MD, CCFP, FRCPC
Medical Officer of Health
Communicable Disease Prevention and Control